Gongwin Biopharm Holdings Co., Ltd. (TPEX:6617)
Taiwan · Delayed Price · Currency is TWD 95.20
-0.90 (-0.94%)
Aug 19, 2026, 1:30 PM CST
Gongwin Biopharm Holdings Market Cap
Gongwin Biopharm Holdings has a market cap or net worth of 11.65 billion as of August 18, 2026. Its market cap has decreased by -7.32% in one year.
Market Cap
11.65B
Enterprise Value
10.23B
Revenue
38.28M
Ranking
n/a
PE Ratio
n/a
Stock Price
95.20
ChartMarket Cap Chart
Since February 8, 2017, Gongwin Biopharm Holdings's market cap has increased from 8.87B to 11.65B, an increase of 31.37%. That is a compound annual growth rate of 2.90%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 19, 2026 | 11.65B | 10.33% |
| Dec 31, 2025 | 10.56B | -26.53% |
| Dec 31, 2024 | 14.37B | -31.28% |
| Dec 29, 2023 | 20.91B | -42.13% |
| Dec 30, 2022 | 36.13B | 16.16% |
| Dec 30, 2021 | 31.10B | 17.15% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Feb 8, 2017 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| TaiMed Biologics | 17.54B |
| Medigen Vaccine Biologics | 16.93B |
| EirGenix | 15.60B |
| Ever Supreme Bio Technology | 14.96B |
| Lumosa Therapeutics | 14.42B |
| ACRO Biomedical | 12.46B |
| AP Biosciences | 10.14B |
| Tanvex BioPharma | 9.98B |